Follow The Filings

HAE Haemonetics Corporation Mass

Health Care, filed as HAEMONETICS CORP MASS (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 1.5%
  • $155M
  • 1 new

In 2026 Q2 John Rogers opened a position in Haemonetics Corporation Mass.

Who owns this now

Largest portfolio weights among holders, up to 1.5% (John Rogers, Ariel Investments). Not free-float ownership.

  1. John Rogers New 1.5%

Who owns HAE

Sorted by value, long equity only, as of 2026 Q2.

History
John Rogers, Ariel Investments 1.5% New 1.5% 2,060,966 $155M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by HAE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All HAE insider trades
  • $99K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Mark W Kroll Director
    Buy
    $99K 1,400 shares at $70.56 +6% to stake
    Traded Nov 10, 2025 Filed Nov 12, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 15 stock grants and 11 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
8-K 7.01 Filing Doc
8-K 7.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Revenue — $1.31B $1.36B $1.33B
Gross profit $615.1M $691.55M $748.96M $787.59M
Gross margin * — 52.8% 55.0% 59.0%
Net income $115.4M $117.56M $167.68M $97.31M
Net margin * — 9.0% 12.3% 7.3%

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $769.72M $768.9M $934.98M $834.88M
Total non-current assets * $1.17B $1.43B $1.52B $1.56B
Total assets $1.93B $2.2B $2.45B $2.4B
Total current liabilities $251.82M $300.38M $578.11M $282.6M
Total equity $818M $959.96M $820.84M $796.32M

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations $273.06M $181.75M $181.72M $293.22M
Cash from investing -$143.79M -$322.39M -$161.9M -$179.55M
Cash from financing -$100.36M $38.16M $108.82M -$178.46M
Net change in cash $24.97M -$105.67M $127.96M -$61.32M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.